Abstract

FORMULATION DEVELOPMENT AND IN-VITRO EVALUATION OF ANTI-CONVULSANT MINI-TABLET EXTENDED-RELEASE DOSAGE FORM

Esukapalli Thirupathi Rao, V. Jhansi Priya Marabathuni* and Naidu Narapusetty

ABSTRACT

Lamotrigine can be used in a minitablet sustained-release drug delivery system and prolong the duration of action in the therapeutic range without reaching toxic levels as in conventional dosage forms. a valuable tool for achieving improved adherence and seizure control, and reduced toxicity. Formulation F9 were exhibited satisfactory physio-chemical characteristics and prepared with HPMC K4M (11 mg) and K100M (4.5 mg) gave 95.4% of desired drug release in 12 hrs also stable in stability. when compared with the optimized formulation decrease release profile. The optimized formulations followed zero order kinetics while the drug release mechanism was found to be Quasi Fickian. On the basis of evaluation parameters, the formulation F9 used once a day administration in the management of epilepsy. These dosage forms have the ability to reduce the dosing frequency.

Keywords: sustained-release drug delivery, epilepsy Quasi Fickian, dosing frequency.